Kromoglicinska kiselina

Kromoglicinska kiselina
(IUPAC) ime
	5,5′-(2-hidroksipropan-1,3-diil)bis(oksi)bis(4-okso-4H-hromen-2-karboksilna kiselina)
Klinički podaci
AHFS/Drugs.com	Internacionalno ime leka
Identifikatori
CAS broj	16110-51-3
ATC kod	A07EB01 D11AH03 R01AC01 R03BC01 S01GX01
PubChem	2882
DrugBank	DB01003
ChemSpider	2779
UNII	Y0TK0FS77W
KEGG	D07753
ChEBI	CHEBI:59773
ChEMBL	CHEMBL74
Hemijski podaci
Formula	C23H16O11
Mol. masa	468,367 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30) ; Key: IMZMKUWMOSJXDT-UHFFFAOYSA-N
Farmakokinetički podaci
Bioraspoloživost	1%
Poluvreme eliminacije	1,3 h
Farmakoinformacioni podaci
Trudnoća	?
Pravni status
Način primene	topikalno, oralno, nazalni sprej

Kromoglicinska kiselina (INN) (cromolyn (USAN), cromoglycate (bivši BAN), ili kromoglikat) je stabilizator mastocita. U prodaji je kao natrijumova so, natrijum kromoglikat ili kromolin natrijum. Ovaj lek sprečava otpuštanje inflamatornih hemikalkija, kao što je histamin, iz mastocita.^[6]^[7]

Leukotrienski antagonisti su u znatnoj meri zamenili ovaj lek, kao preferentni nekortikosteroidni tretmant za tretiranje astme. Kromoglicinsku keselinu je neophodno administrirati četiri puta dnevno, i ona nema dodatnih prednosti u kombinaciji sa kortikosteroidima unetim putem inhalacije.^[8]

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. PMID 21059682.
↑ Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. PMID 18048412.
↑ Fanta CH (March 2009). „Asthma”. New England Journal of Medicine 360 (10): 1002–14. DOI:10.1056/NEJMra0804579. PMID 19264689. Review.

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. PMID 21059682.

[7] Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. PMID 18048412.

[8] Fanta CH (March 2009). „Asthma”. New England Journal of Medicine 360 (10): 1002–14. DOI:10.1056/NEJMra0804579. PMID 19264689. Review.

[6]

[7]

[1]

[2]

[3]

[4]

[5]

[8]